John M. Pagel

Appointments and Affiliations
 
 
Fred Hutchinson Cancer Research Center
Transplant Oncology
Clinical Research
Assistant Member, Appointed: 2005
 Professional Headshot of John M. Pagel

Mailing Address

1100 Fairview Avenue North
Suite D5-380
Seattle, Washington 98109-1024
United States

Contact

Phone: (206) 667-1868
Fax: (206) 667-4111
jpagel@fhcrc.org
http://labs.fhcrc.org/pagel/index.html
 

Degrees

Acting Instructor, University of Washington, Department of Medicine, Division of Oncology, 2005.
Associate in Clinical Research, Fred Hutchinson Cancer Research Center, 2002.
Senior Fellow, Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Oncology, 1999.
Internal Medicine Residency, University of California, San Francisco, Department of Medicine, 1999.
Internal Medicine Internship, University of California, San Francisco, Department of Medicine, 1997.
M.D., Magna cum laude, Boston University, School of Medicine, 1996.
Post-doctoral, University of California, San Francisco, Howard Hughes Research Associate, 1992.
Ph.D., University of California, Irvine, Microbiology and Molecular Genetics, 1991.

Research Interests

Dr. Pagel leads leukemia studies of radioimmunotherapy at the Center as the principal investigator of several human clinical trials. He is working to increase the usefulness of antibody therapy by "pretargeting" radiation directly to the cells. He is also researching nonradioactive chemical partners to antibodies.

Memberships

American Society for Blood and Marrow Transplantation
American Society of Hematology
European Association of Nuclear Medicine
Puget Sound Oncology Consortium

Honors and Awards

2005, Clinical Investigator Award, Damon Runyon Cancer Research Foundation
2004, Career Development Award, Lymphoma Research Foundation
2004, Career Development Award, ASCO
2002, Young Investigator Award, ASCO
1994, Pathology Honor Society, Assoc. of Pathology Chairs, BU School of Medicine
1994, Alpha Omega Alpha Medical Honor Society, BU School of Medicine
1993, Family Medicine Interest Gr. Leadership Award, Am. Academy of Family Physicians
1991-1992, Howard Hughes Post-doctoral Research Award, UCSF
1988-1991, National Institutes of Health Pre-doctoral Fellow, UC Irvine
1986, Univ. of California Undergraduate Research Award, UC Riverside
1985, University of California Presidents Award, UC Riverside
1982, Bank of America Academic Leadership Award, UCLA
1982-1986, Mountains Community Hospital Health Profession Scholarship, UCLA
1982, University of California Chancellor's Scholarship, UCLA
1982-1983, Ralph J. Bunche Academic Scholarship, UCLA

 

Recent Publications

2013
Orozco, JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur SD, Fisher DR, Frayo SL, Hylarides MD, Green DJ et al..  2013.  Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.. Blood. Abstract
Budde, LE, Zhang MM, Shustov AR, Pagel JM, Gooley TA, Oliveira GR, Chen TL, Knudsen NL, Roden JE, Kammerer BE et al..  2013.  A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.. British journal of haematology. Abstract
2012
Hattori, N, Gopal AK, Shields AT, Fisher DR, Gooley T, Pagel JM, Press OW, Rajendran JG.  2012.  131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.. Nuclear medicine communications. 33(12):1225-31. Abstract
Karp, JE, Garrett-Mayer EL, Estey EH, Rudek MA, Smith DB, Greer JM, Drye MD, Mackey K, Dorcy KS, Gore SD et al..  2012.  Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.. Haematologica. Abstract
Deeg, HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP et al..  2012.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.. Blood. 120(7):1398-408. Abstract
Deeg, HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP et al..  2012.  Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.. Blood. 120(7):1398-408. Abstract
Till, BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE et al..  2012.  CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.. Blood. 119(17):3940-50. Abstract
2011
Becker, PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer BE, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR et al..  2011.  Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.. British journal of haematology. 155(2):182-9. Abstract
Ram, R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH, Shustov AR, Flowers MED, O'Donnell PV, Sandmaier BM et al..  2011.  Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(10):1537-45. Abstract
Walter, RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk E, Chien JW et al..  2011.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(9):1190-7. Abstract
Nemecek, ER, Guthrie KA, Sorror ML, Wood BL, Doney K, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE et al..  2011.  Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(3):341-50. Abstract
Eissa, H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, Loeb KR, Martin PJ, Pagel JM, Radich JP et al..  2011.  Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(6):908-15. Abstract
Gopal, AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG, Matesan MC, Storb R, Press OW.  2011.  90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.. Blood. 118(4):1132-9. Abstract
Pagel, JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur SD, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N et al..  2011.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.. Blood. 118(3):703-11. Abstract
Park, SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur SD, Stayton PS, Orgun N, Hylarides M, Buchegger F et al..  2011.  Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23):7373-82. Abstract
Budde, LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg L, Shustov AR et al..  2011.  Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9. Abstract
2010
Woolfrey, AE, Lee SJ, Gooley TA, Malkki M, Martin PJ, Pagel JM, Hansen JA, Petersdorf EW.  2010.  HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(10):1382-7. Abstract
Park, SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur SD, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T et al..  2010.  Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.. Blood. 116(20):4231-9. Abstract
Shenoi, J, Gopal AK, Press OW, Pagel JM.  2010.  Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation.. Current opinion in oncology. 22(2):143-9. Abstract
Wilbur, SD, Park SI, Chyan M-K, Wan F, Hamlin DK, Shenoi J, Lin Y, Wilbur SM, Buchegger F, Pantelias A et al..  2010.  Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.. Bioconjugate chemistry. 21(7):1225-38. Abstract
Walter, RB, Pagel JM, Gooley TA, Petersdorf EW, Sorror ML, Woolfrey AE, Hansen JA, Salter AI, Lansverk E, Stewart FM et al..  2010.  Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 24(7):1276-82. Abstract
Gopal, AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE et al..  2010.  Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.. Leukemia & lymphoma. 51(8):1523-9. Abstract
Alyea, EP, DeAngelo DJ, Moldrem J, Pagel JM, Przepiorka D, Sadelin M, Young JW, Giralt S, Bishop M, Riddell SR.  2010.  NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignan. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 16(8):1037-69. Abstract
Walter, RB, Press OW, Pagel JM.  2010.  Pretargeted radioimmunotherapy for hematologic and other malignancies.. Cancer biotherapy & radiopharmaceuticals. 25(2):125-42. Abstract
2009
Wilbur, SD, Thakar MS, Hamlin DK, Santos EB, Chyan M-K, Nakamae H, Pagel JM, Press OW, Sandmaier BM.  2009.  Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.. Bioconjugate chemistry. 20(10):1983-91. Abstract